A Phase I-II 2ccPA Study in Patients With Symptomatic Knee
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This phase I/II study aims to evaluate the safety of single doses of 2ccPA 4,800 μg and 7,200
μg (Phase I), as well as the safety and efficacy of multiple doses of 2ccPA (Phase II) in
patients with osteoarthritis (OA) of the knee.